COVID-19 Saliva Screening Test Potential Market Report 2025

This COVID-19 Saliva Screening Test Potential market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The COVID-19 saliva screening test potential market size has grown strongly in recent years. It will grow from $3.9 billion in 2024 to $4.29 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to the potential for home testing, unprecedented need for diagnostic testing, rise in public awareness, and research and development investment.

The COVID-19 saliva screening test potential market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to integration with screening programs, regulatory support, growing demand for speedy, point-of-care COVID-19 tests, increasing population, and the rise of e-commerce. Major trends in the forecast period include increasing adoption in non-healthcare settings, integration with digital health platforms, emergence of next-generation technologies, technological advancements, and strategic partnerships.

The growing healthcare expenditure is expected to drive the expansion of the COVID-19 saliva screening test market in the coming years. Healthcare expenditure includes all spending on healthcare-related products and services, such as prescription medications, hospital stays, doctor visits, medical equipment, and public health initiatives. The rise in healthcare expenditure is driven by factors like minimally invasive surgeries, advanced diagnostic technologies, increased research and development for new drugs, greater utilization of healthcare services, and the use of specialty medications. Higher healthcare spending provides the resources needed to fully leverage the potential of COVID-19 saliva screening tests, leading to more effective pandemic management and improved public health outcomes. For example, in 2022, according to the Office for National Statistics, the UK’s healthcare expenditure reached around $354.88 billion (£283 billion), marking a slight increase of 0.7% compared to 2021. Therefore, the increase in healthcare expenditure is fueling the growth of the COVID-19 saliva screening test market.

Key players in the COVID-19 saliva screening test market are focusing on developing innovative technologies, such as data-sharing platforms, to improve real-time communication and collaboration among healthcare providers, laboratories, and public health authorities. This helps enhance the efficiency and accuracy of testing, tracking, and response efforts during the pandemic. Data-sharing platforms are digital systems that enable secure data exchange between various stakeholders, including healthcare providers, researchers, and organizations. They promote collaboration and facilitate access to information, thereby improving decision-making, efficiency, and outcomes across sectors. For example, in May 2024, Mount Sinai Health System, a US-based healthcare network, launched the Center for Healthcare Readiness. The Center is focused on enhancing strategies for public health emergency response, ensuring that healthcare systems can effectively manage large-scale crises, such as pandemics or natural disasters. It aims to strengthen the capacity of the Mount Sinai Health System and work with local, regional, and federal partners to develop comprehensive preparedness plans.

In July 2024, Hologic, Inc., a US-based health technology company, acquired Endomagnetics Ltd. for an undisclosed amount. Through this acquisition, Hologic, Inc. aims to broaden its portfolio of innovative healthcare solutions and expand its presence in the women's health market. Endomagnetics Ltd. is a UK-based medical technology company that develops devices designed to detect cancerous lymph nodes during surgery.

Major companies operating in the COVID-19 saliva screening test potential market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, University of North Carolina at Chapel Hill, Hologic Inc., Beaumont Health, PerkinElmer Inc., Quidel Corporation, University of Illinois at Urbana-Champaign, Cepheid, Seegene Inc., ARUP Laboratories, Vatic Health Limited, Ambry Genetics Corporation, LumiraDx Ltd., Yale School of Public Health, Gravity Diagnostics, Psomagen Inc., Fluidigm Corporation, Phosphorus Diagnostics LLC, DxTerity Diagnostics Inc., University of Notre Dame, MOgene, FLuroTech Ltd.

North America was the largest region in the COVID-19 saliva screening test potential market in 2024. The regions covered in the COVID-19 saliva screening test potential market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 saliva screening test potential market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The potential of saliva-based COVID-19 screening tests pertains to the possible benefits and capabilities they offer in comparison to conventional methods such as nasopharyngeal or oropharyngeal swab tests for detecting the SARS-CoV-2 virus, which causes COVID-19. This potential encompasses enhancements in testing accessibility, patient acceptance, cost-effectiveness, and safety, while also facilitating the adoption of new testing strategies and approaches for better management of the pandemic.

Key locations where the potential of COVID-19 saliva screening tests is prominent include travel stations, sports arenas, entertainment venues, corporate campuses, universities and colleges, factories, and similar settings. Travel stations are specifically designated areas within transportation hubs where individuals can undergo COVID-19 saliva screening tests before commencing their journeys. These tests utilize various technologies such as fluorescence-labeled antigen, rt-PCR, and CRISPR-Cas9, with testing conducted through centralized or decentralized approaches.

The COVID-19 saliva screening test potential market research report is one of a series of new reports that provides COVID-19 saliva screening test potential market statistics, including COVID-19 saliva screening test potential industry global market size, regional shares, competitors with a COVID-19 saliva screening test potential market share, detailed COVID-19 saliva screening test potential market segments, market trends, and opportunities, and any further data you may need to thrive in the COVID-19 saliva screening test potential industry. This COVID-19 saliva screening test potential market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The COVID-19 saliva screening test potential market consist revenues earned by entities by providing services such as sample collection services, laboratory testing services, diagnostic reporting services, and screening and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The COVID-19 saliva screening test potential market also consists of sales of saliva collection kits, rapid saliva testing kits, laboratory testing supplies, and automated sample processing systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.